Newsroom

Isoray Announces Second Quarter Fiscal 2021 Financial Results

Revenue Increased 7% Year-Over-Year Non-Prostate Brachytherapy Revenue Increased 92% Year-Over-Year   RICHLAND, WASHINGTON – February 9, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding...

read more

Isoray Announces Pricing of $45 Million Public Offering

RICHLAND, Wash., February 4, 2021 - Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, announced the pricing of its public offering of 36,000,000 shares of its...

read more

Isoray Announces Proposed Underwritten Public Offering

RICHLAND, Wash., February 3, 2021 - Isoray, Inc. (NYSE AMERICAN: ISR) (“Isoray” or the “Company”), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that it intends to offer and...

read more
New Research on Cesium Blu Presented at ASTRO

New Research on Cesium Blu Presented at ASTRO

With over ten years of data on Cesium Blu, researchers continue to study its value in powering modern brachytherapy.  ASTRO 2020 showcased multiple new e-posters and papers that can now be easily accessed online.   A Matched Pair Analysis Of Clinical Outcomes...

read more

Investor Relations:

Mark Levin

Global IR Group
(501) 255-1910

Media and Public Relations:

Sharon Schultz
Schultz Public Relations
(302) 539-3747
schultzpr@mchsi.com